Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2009 1
2010 2
2013 1
2017 3
2019 1
2021 1
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Showing results for free ar[au]
Your search for Frew AR[au] retrieved no results
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience.
Özbalak M, Güzel Mastanzade M, Özlük Ö, Tiryaki TO, Erdem S, Özbalak EP, Elverdi T, Yönal Hindilerden İ, Altay AY, Yeğen G, Eşkazan AE, Ar MC, Yenerel MN, Soysal T, Nalçacı M, Ferhanoğlu B, Kalayoğlu Beşışık S. Özbalak M, et al. Among authors: ar mc. Turk J Haematol. 2022 Dec 1;39(4):254-261. doi: 10.4274/tjh.galenos.2022.2022.0142. Epub 2022 Jun 3. Turk J Haematol. 2022. PMID: 35657203 Free PMC article.
In the historical MAB cohort, the ORR was 84%, with CR and PR rates of 82% and 2%, respectively. The 24-month progression-free survival (PFS) rates were 73.76% (95% confidence interval [CI]: 0.59-0.84) and 85.2% (95% CI: 0.79-0.90) for the RED and MAB cohorts, respectively …
In the historical MAB cohort, the ORR was 84%, with CR and PR rates of 82% and 2%, respectively. The 24-month progression-free surviv …
Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.
Eşkazan AE, Özmen D, Öztaş M, Bektaş F, Bayraktar EA, Sadri S, Keskin D, Özgür Yurttaş N, Elverdi T, Salihoğlu A, Ar MC, Öngören Ş, Başlar Z, Aydın Y, Soysal T. Eşkazan AE, et al. Among authors: ar mc. Clin Lymphoma Myeloma Leuk. 2021 Aug;21(8):549-557. doi: 10.1016/j.clml.2021.04.005. Epub 2021 Apr 20. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34052176
Cumulative response rates were similar in both groups. Event-free survival was comparable, and overall survival (OS)-when non-CML-related deaths were censored-was also similar. ...
Cumulative response rates were similar in both groups. Event-free survival was comparable, and overall survival (OS)-when non-CML-rel …
Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study.
Ozbalak M, Ar MC, Tuzuner N, Salihoglu A, Eskazan AE, Ongoren Aydin S, Baslar Z, Soysal T, Aydin Y, Barak Dolgun A, Ergonul O, Ferhanoglu B. Ozbalak M, et al. Among authors: ar mc. ISRN Hematol. 2013 Jul 30;2013:908191. doi: 10.1155/2013/908191. eCollection 2013. ISRN Hematol. 2013. PMID: 23984080 Free PMC article.

Rituximab significantly improved the 3- and 5-year progression free survival (PFS) (70% versus 65% and 41% versus 36%, resp.; P < 0.001) but led only to a slight, insignificant increase in 3- and 5-year overall survival (OS) (71% versus 77.3% and %67 versus 74.5%, resp.

…
Rituximab significantly improved the 3- and 5-year progression free survival (PFS) (70% versus 65% and 41% versus 36%, resp.; P < …
The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
Soysal T, Eskazan AE, Serin I, Sadri S, Keskin D, Ozgur Yurttas N, Berk S, Erdogan Ozunal I, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Ozbek U, Aydin Y. Soysal T, et al. Among authors: ar mc. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e377-e384. doi: 10.1016/j.clml.2019.03.028. Epub 2019 Apr 4. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31088736
Patients with WR at 3 months had significantly inferior failure-free survival (FFS) than optimal responders, but overall survival (OS) was similar. ...
Patients with WR at 3 months had significantly inferior failure-free survival (FFS) than optimal responders, but overall survival (OS …
Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.
Öngören Ş, Eşkazan AE, Berk S, Elverdi T, Salihoğlu A, Ar MC, Başlar Z, Aydın Y, Tüzüner N, Soysal T. Öngören Ş, et al. Among authors: ar mc. Turk J Haematol. 2017 Dec 1;34(4):291-299. doi: 10.4274/tjh.2016.0443. Turk J Haematol. 2017. PMID: 29199176 Free PMC article.
Relapse rates were significantly lower in patients who received first-line 2-CdA. The progression-free survival (PFS) rate with 2-CdA was significantly higher than in patients with INF-alpha and splenectomy, but we found similar overall survival rates with all three upfron …
Relapse rates were significantly lower in patients who received first-line 2-CdA. The progression-free survival (PFS) rate with 2-CdA …
In vivo demonstration of the absorptive function of the middle ear epithelium.
Li JP, Kania R, Lecain E, Ar A, Sauvaget E, Tran Ba Huy P, Herman P. Li JP, et al. Among authors: ar a. Hear Res. 2005 Dec;210(1-2):1-8. doi: 10.1016/j.heares.2005.04.011. Epub 2005 Oct 26. Hear Res. 2005. PMID: 16256284
The rate of absorption is high enough to allow total clearance of fluid from the cavity of the middle ear within 13 h. This process might play a role in the maintaining a fluid-free and gas-filled middle ear cavity....
The rate of absorption is high enough to allow total clearance of fluid from the cavity of the middle ear within 13 h. This process might pl …
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.
Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Devidas M, Mullighan CG, Wang X, Murphy M, Ar K, Wharton W, Borowitz MJ, Bowman WP, Bhojwani D, Carroll WL, Camitta BM, Reaman GH, Smith MA, Downing JR, Hunger SP, Willman CL. Kang H, et al. Among authors: ar k. Blood. 2010 Feb 18;115(7):1394-405. doi: 10.1182/blood-2009-05-218560. Epub 2009 Oct 30. Blood. 2010. PMID: 19880498 Free PMC article. Clinical Trial.
To determine whether gene expression profiling could improve outcome prediction in children with acute lymphoblastic leukemia (ALL) at high risk for relapse, we profiled pretreatment leukemic cells in 207 uniformly treated children with high-risk B-precursor ALL. A 38-gene expres …
To determine whether gene expression profiling could improve outcome prediction in children with acute lymphoblastic leukemia (ALL) at high …
Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.
Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, Ar K, Xu Y, Kopecky KJ, Ankerst DP, Gundacker H, Slovak ML, Mosquera-Caro M, Chen IM, Stirewalt DL, Murphy M, Schultz FA, Kang H, Wang X, Radich JP, Appelbaum FR, Atlas SR, Godwin J, Willman CL. Wilson CS, et al. Among authors: ar k. Blood. 2006 Jul 15;108(2):685-96. doi: 10.1182/blood-2004-12-4633. Epub 2006 Apr 4. Blood. 2006. PMID: 16597596 Free PMC article.

Unsupervised clustering methods were used to classify patients into 6 cluster groups (designated A to F) that varied significantly in rates of resistant disease (RD; P < .001), complete response (CR; P = .023), and disease-free survival (DFS; P = .023). Cluster A (n = 2

…
Unsupervised clustering methods were used to classify patients into 6 cluster groups (designated A to F) that varied significantly in rates …
Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.
Yalnız FF, Akkoç N, Salihoğlu A, Ar MC, Öngören Ş, Eşkazan AE, Soysal T, Aydın Y. Yalnız FF, et al. Among authors: ar mc. Turk J Haematol. 2017 Aug 2;34(3):233-238. doi: 10.4274/tjh.2016.0397. Epub 2017 Mar 8. Turk J Haematol. 2017. PMID: 28270368 Free PMC article.
Sixty-eight percent of patients had progressive disease. The median progression-free survival and overall survival was 2 and 4 months, respectively. ...
Sixty-eight percent of patients had progressive disease. The median progression-free survival and overall survival was 2 and 4 months …
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
Eskazan AE, Sadri S, Keskin D, Ayer M, Kantarcioglu B, Demirel N, Aydin D, Aydinli F, Yokus O, Ozunal IE, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: ar mc. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):804-811. doi: 10.1016/j.clml.2017.07.255. Epub 2017 Aug 4. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28847475
Patients with an optimal response (OR) at both 3 and 6 months had significantly superior event-free survival rates compared with patients without an OR in groups A and B. CONCLUSION: The results of the present study have demonstrated most probably for the first time that a …
Patients with an optimal response (OR) at both 3 and 6 months had significantly superior event-free survival rates compared with pati …
12 results